Pembrolizumab toxicity

Evidence-based neurology checklist on pembrolizumab toxicity: Peripheral neurological features Axonal peripheral neuropathy (PN) Myasthenia gravis (MG) Myositis Necrotic myositis Polyradiculopathy Vasculitic neuropathy Miller Fisher syndrome (MFS) Central neurological features Renal features…

Peripheral neurological features

  • Axonal peripheral neuropathy (PN)
  • Myasthenia gravis (MG)
  • Myositis
  • Necrotic myositis
  • Polyradiculopathy
  • Vasculitic neuropathy
  • Miller Fisher syndrome (MFS)

Central neurological features

Renal features

Dermatological features

Ophthalmological features

Haematological features

Pulmonary features

Hepatobiliary features

Endocrine features

Cardiac features

Rheumatological features

Gastrointestinal features

References

  1. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29:806-812.
  2. Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017; 32:936-942.
  3. Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother 2017; 40:221-223.
  4. Yen CC, Su HC, Chu CY, et al. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. Lung Cancer 2018; 120:149-151.
  5. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017; 82:128-136. 
  6. And 61 more. Subscribe to see the full list

Related checklists

Loading...